Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 131fludarabine phosphate 108Mycophenolic Acid 92Peripheral Blood Stem Cell Transplantation 91Whole-Body Irradiation 80Tacrolimus 78Busulfan 64Cyclosporine 60fludarabine 55Melphalan 55Filgrastim 54Antilymphocyte Serum 48Methotrexate 41Radiotherapy 39Etoposide 35Rituximab 33Granulocyte Colony-Stimulating Factor 27Sirolimus 25Cytarabine 23Stem Cell Transplantation 21Cord Blood Stem Cell Transplantation 21thymoglobulin 20Thiotepa 19Methylprednisolone 18sargramostim 17Cyclosporins 16Carmustine 16Alemtuzumab 16Therapeutics 13Psychiatric Rehabilitation 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × tinostamustine × Other hematologic neoplasm × Clear all
NCT02576496 2024-07-25

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Mundipharma Research Limited

Phase 1 Completed
106 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡